Today: 7 February 2026
Subscribe
Browse Category

NYSE:JNJ News 18 January 2026 - 28 January 2026

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly shares closed down 2.3% at $1,039.51 Tuesday, then rose 0.3% after hours. U.S. Medicare officials named Lilly’s Trulicity among 15 drugs for 2028 price negotiations. The stock has dropped three straight sessions and now trades about 8% below its Jan. 8 peak. Investors await Lilly’s Feb. 4 earnings for updates on diabetes and obesity drug trends.
28 January 2026
·······
Johnson & Johnson stock is nudging higher — here’s what traders are watching this week

Johnson & Johnson stock is nudging higher — here’s what traders are watching this week

Johnson & Johnson shares rose 0.4% to $221.01 Monday as investors awaited the Federal Reserve’s Jan. 28 decision and major tech earnings. The company projected 2026 adjusted earnings per share of $11.43–$11.63 and sales up to $101 billion. A court-appointed special master recommended allowing expert testimony that J&J’s talc caused ovarian cancer, raising the risk of federal trials. J&J denies the allegations.
26 January 2026
·
Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

The Health Care Select Sector SPDR Fund (XLV) fell 0.5% to $157.48 Friday, with Eli Lilly down 2.1%. Johnson & Johnson and UnitedHealth posted small gains. Traders are watching obesity-drug demand and a crowded earnings calendar next week. The FDA linked ByHeart’s recalled infant formula to a multi-state botulism outbreak.
25 January 2026
·····
Johnson & Johnson stock ends higher; what to watch for JNJ price after Fed week and talc risk

Johnson & Johnson stock ends higher; what to watch for JNJ price after Fed week and talc risk

Johnson & Johnson shares rose 0.76% to $220.14 at Friday’s close, outpacing other major pharma stocks. The company reaffirmed its 2026 sales and profit targets after posting Q4 sales of $24.6 billion and adjusted EPS of $2.46. Legal risks remain as a special master recommended expert testimony in federal talc lawsuits. Investors await the Federal Reserve’s rate decision on Wednesday.
25 January 2026
··
Johnson & Johnson stock price ends week near $220 as Wall Street hikes targets — what to watch next

Johnson & Johnson stock price ends week near $220 as Wall Street hikes targets — what to watch next

Johnson & Johnson shares closed Friday up 0.8% at $220.14 after TD Cowen and Citi raised price targets to $250, citing strong 2026 guidance. Q4 2025 sales reached $24.6 billion with adjusted EPS at $2.46. A court special master recommended allowing expert testimony in federal talc lawsuits. The company declared a $1.30 quarterly dividend, payable March 10.
24 January 2026
·
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead Sciences shares rose 3.5% to $135.73 Friday, hitting new highs after Phase 3 trial data showed its Trodelvy-Keytruda combo cut the risk of disease progression or death by 35% in metastatic triple-negative breast cancer. Gilead has filed for expanded approval in the U.S. and Europe. Volume reached 8.8 million shares. A Form 144 filing showed executive Deborah Telman plans to sell up to 29,215 shares.
23 January 2026
·····
Johnson & Johnson stock today: Why JNJ can’t break out as talc risk shadows upbeat 2026 outlook

Johnson & Johnson stock today: Why JNJ can’t break out as talc risk shadows upbeat 2026 outlook

Johnson & Johnson shares traded nearly flat at $218.59 by late Friday morning as Wall Street upgrades met renewed worries over federal talc lawsuits. A special master recommended allowing plaintiffs’ experts to testify that J&J talc products can cause ovarian cancer, affecting over 67,500 cases. The company reported Q4 sales up 9.1% to $24.6 billion and projected 2026 sales of up to $101 billion.
23 January 2026
··
Johnson & Johnson stock price today: JNJ ends higher, but talc case stays in focus after earnings

Johnson & Johnson stock price today: JNJ ends higher, but talc case stays in focus after earnings

Johnson & Johnson closed up 0.3% at $218.49 Thursday after reporting Q4 revenue of $24.56 billion and adjusted earnings of $2.46 per share. The company projected 2026 sales above estimates but faces ongoing pressure from U.S. drug pricing, tariffs, and talc litigation. A court-appointed special master recommended allowing expert testimony in the New Jersey talc case. J&J plans to appeal.
22 January 2026
···
Johnson & Johnson stock price rises today as investors weigh 2026 outlook — and talc lawsuit clock

Johnson & Johnson stock price rises today as investors weigh 2026 outlook — and talc lawsuit clock

Johnson & Johnson shares rose 1.1% to $220.36 Thursday after the company posted fourth-quarter sales of $24.564 billion and adjusted EPS of $2.46, beating forecasts. J&J projected 2026 adjusted EPS of $11.43–$11.63 and sales up to $101 billion. The company warned of a $500 million tariff hit and ongoing legal risks from talc lawsuits. Investors reacted to declining Stelara sales and competition in medical devices.
22 January 2026
·
Johnson & Johnson stock price swings late as JNJ guidance beats views, but talc risk grabs traders again

Johnson & Johnson stock price swings late as JNJ guidance beats views, but talc risk grabs traders again

Johnson & Johnson shares slipped 0.05% to $218.01 in after-hours trading Wednesday after the company projected 2026 sales and profits above Wall Street estimates. Investors weighed the upbeat forecast against renewed legal risks as a court-appointed special master recommended allowing expert testimony in federal talc litigation involving over 67,500 lawsuits. J&J plans to appeal the ruling.
22 January 2026
···
Why Johnson & Johnson stock is slipping today after JNJ’s 2026 forecast

Why Johnson & Johnson stock is slipping today after JNJ’s 2026 forecast

Johnson & Johnson shares fell 1.3% to $215.31 after its 2026 outlook and Q4 results, as renewed legal risks and pricing pressures weighed on investors. The company reported Q4 sales of $24.564 billion and forecasted 2026 adjusted EPS of $11.43–$11.63. Legal pressure increased after a special master advised allowing expert testimony in talc cancer lawsuits. Tariff risks and Stelara's decline added to market concerns.
21 January 2026
·
Johnson & Johnson stock price slips after-hours ahead of earnings as tariff fears rattle markets

Johnson & Johnson stock price slips after-hours ahead of earnings as tariff fears rattle markets

Johnson & Johnson shares slipped 0.2% to $218.21 in after-hours trading Tuesday ahead of quarterly earnings due Wednesday. The move followed a broad market selloff, with the Dow down 1.76% and the S&P 500 off 2.06% after new U.S. tariff threats. Analysts expect Q4 profit of $2.47 per share. The company faces ongoing litigation, including a $1.5 billion verdict over talc products.
21 January 2026
··
Dow Jones futures drop on Trump tariff threat as Wall Street sets up for Netflix, PCE week

Dow Jones futures drop on Trump tariff threat as Wall Street sets up for Netflix, PCE week

The Dow closed down 0.2% at 49,359.33 on Friday ahead of the MLK Day market holiday. Dow futures fell 0.7% after President Trump threatened a 10% tariff on imports from eight European nations tied to Greenland, with the rate set to rise to 25% in June if talks fail. European leaders condemned the move and gold hit new highs as investors sought safety. Traders await key earnings and Thursday’s PCE inflation data.
19 January 2026
·····
Trump’s Greenland tariff threat sets up a tense week for global stocks

Trump’s Greenland tariff threat sets up a tense week for global stocks

President Donald Trump threatened 10% tariffs on eight European countries tied to Greenland, escalating to 25% by June if no deal is reached. The S&P 500 closed nearly flat at 6,940.01, while the Dow and Nasdaq also posted slight losses. Europe’s STOXX 600 ended flat, and China’s regulator announced tighter market controls. U.S. markets will close Monday for Martin Luther King Jr. Day.
18 January 2026
···
Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson shares closed down 0.4% at $218.66 Friday ahead of the Martin Luther King Jr. Day market holiday. The S&P 500 health care sector fell 0.8%. J&J reports fourth-quarter results Wednesday, Jan. 21, with investors focused on earnings and 2026 guidance. The NYSE will reopen Tuesday after the holiday.
18 January 2026
·······
Supreme Court Fed showdown, Davos and China GDP: what to watch in global markets next week

Supreme Court Fed showdown, Davos and China GDP: what to watch in global markets next week

The U.S. Supreme Court will hear arguments Wednesday on President Trump’s effort to remove Fed Governor Lisa Cook. Stocks ended the week lower, with the S&P 500 at 6,940.01 and Brent crude at $64.13. China releases GDP data as Davos opens, while Japan nears a possible snap election. Prime Minister Takaichi may suspend Japan’s 8% food sales tax, risking a 5 trillion yen revenue hit.
18 January 2026
····
1 2 3 4 … 7

Stock Market Today

Bank of America stock jumps 3% into the weekend — what to watch before Monday’s trade

Bank of America stock jumps 3% into the weekend — what to watch before Monday’s trade

7 February 2026
Bank of America shares rose 2.89% Friday to $56.53, tracking a rally in U.S. financial stocks as the Dow closed above 50,000. The bank will redeem its Series DD preferred stock and related depositary shares on March 10 at $1,000 per share. CEO Brian Moynihan donated 100,000 shares on Feb. 4, a regulatory filing showed. Key U.S. jobs and inflation data are due next week after delays.
Oracle stock rebounds from eight-day skid as $20 billion share-sale plan looms

Oracle stock rebounds from eight-day skid as $20 billion share-sale plan looms

7 February 2026
Oracle shares jumped 4.65% to $142.82 Friday, ending an eight-day slide but remaining down 22% since Jan. 27. The company has set up a $20 billion at-the-market stock program and completed a $25 billion senior notes sale to fund cloud expansion. Oracle’s liabilities stood at $174.5 billion as of Nov. 30, 2025, before the new financing. Investors remain focused on dilution risks and the pace of capacity growth.
ASML stock price snaps back as AI spending bets return, with ex-dividend date next

ASML stock price snaps back as AI spending bets return, with ex-dividend date next

7 February 2026
ASML shares rose 3.84% Friday in Amsterdam to 1,193.80 euros, rebounding with global chip stocks after Amazon signaled a sharp increase in AI-related capital spending. The stock goes ex-dividend Feb. 9 ahead of a 1.60-euro interim payout. ASML’s Nasdaq shares climbed 4.64% to $1,413.01. Despite Friday’s gains, the Amsterdam listing finished the week about 2.5% lower.
Mastercard stock price: MA slips as Dow hits 50,000; jobs and CPI data next week

Mastercard stock price: MA slips as Dow hits 50,000; jobs and CPI data next week

7 February 2026
Mastercard shares closed down 0.6% at $548.74 Friday, trailing gains in Visa and American Express. The Dow Jones Industrial Average surged 2.47% to a record 50,115.67. Mastercard disclosed a new cybersecurity partnership in the UAE and raised compensation for two top executives. U.S. jobs and inflation data, delayed by a government shutdown, are due next week.
Go toTop